CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer.
An Ionic Liquid Ablation Agent for Local Ablation and Immune Activation in Pancreatic Cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
胰腺导管腺癌迅速对化疗产生耐药性,仍是一种致命性疾病。免疫治疗是癌症治疗的突破之一,包括免疫检查点抑制剂、CAR-T 细胞免疫治疗和新抗原疫苗。然而,免疫治疗在胰腺癌治疗中尚未取得令人满意的结果。免疫原性死亡包括促炎性细胞死亡,为增强肿瘤免疫原性并促进实体瘤中的免疫反应提供了一种途径。本文描述了一种由胆碱和香叶酸合成的离子液体消融剂(LAA),通过将免疫抑制性“冷”肿瘤重塑为免疫激活的“热”肿瘤,触发坏死诱导的免疫治疗。结果表明,LAA处理的肿瘤细胞可以增强免疫原性,诱导树突状细胞成熟、巨噬细胞M1极化和细胞毒性T淋巴细胞浸润。本研究结果为实体瘤免疫治疗提供了一种新策略。
Pancreatic ductal adenocarcinoma rapidly acquires resistance to chemotherapy, remaining a fatal disease. Immunotherapy is one of the breakthroughs in cancer treatment, which includes immune checkpoint inhibitors, chimeric antigen receptor T-cell immunotherapy, and neoantigen vaccines.
However, immunotherapy has not achieved satisfactory results in the treatment of pancreatic cancer. Immunogenic death comprises proinflammatory cell death, which provides a way to enhance tumor immunogenicity and promote an immune response in solid tumors.
Herein, an ionic liquid ablation agent (LAA), synthesized from choline and geranic acid, which triggers necrosis-induced immunotherapy by remodeling an immunosuppressive "cold" tumor to an immune activated "hot" tumor is described. The results indicate that LAA-treated tumor cells can enhance immunogenicity, inducing dendritic cell maturation, macrophage M1 polarization, and cytotoxic T lymphocyte infiltration. The results of the present study provide a novel strategy for solid tumor immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。